Hyperhomocysteinemia alters cytokine gene expression, cytochrome c oxidase activity and oxidative stress in striatum and cerebellum of rodents

Santos, Tiago Marcon dos; Júnior, Osmar Vieira Ramires; Alves, Vinícius Santos; Coutinho‐Silva, Robson; Savio, Luiz Eduardo Baggio; Wyse, Ângela T. S.

doi:10.1016/j.lfs.2021.119386

Cited by 8 publications

(5 citation statements)

References 76 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The same authors showed that the IL-10 mRNA levels were manifestly downregulated in the brain of spontaneously hypertensive rats with elevated blood concentration of Hcy [ 36 ]. Another study demonstrated that HHC decreased TNF-α and increased IL-1β gene expression in the striatum of rats while in the cerebellum, expression of TNF-α, IL-1β, IL-10, and TGF-β was increased [ 37 ]. In the present work, we demonstrated for the first time that gestational HHC decreased IL-10 content in the hippocampus of rats on P20, which, together with glia activation and the increase in IL-6 and IL-1β levels, suggests stronger inflammatory response to stressful stimuli in this structure than in the cortex.…”

Section: Discussionmentioning

confidence: 99%

Prenatal Hyperhomocysteinemia Induces Glial Activation and Alters Neuroinflammatory Marker Expression in Infant Rat Hippocampus

Shcherbitskaia

Vasilev

Milyutina

et al. 2021

Cells

View full text Add to dashboard Cite

Maternal hyperhomocysteinemia is one of the common complications of pregnancy that causes offspring cognitive deficits during postnatal development. In this study, we investigated the effect of prenatal hyperhomocysteinemia (PHHC) on inflammatory, glial activation, and neuronal cell death markers in the hippocampus of infant rats. Female Wistar rats received L-methionine (0.6 g/kg b.w.) by oral administration during pregnancy. On postnatal days 5 and 20, the offspring’s hippocampus was removed to perform histological and biochemical studies. After PHHC, the offspring exhibited increased brain interleukin-1β and interleukin-6 levels and glial activation, as well as reduced anti-inflammatory interleukin-10 level in the hippocampus. Additionally, the activity of acetylcholinesterase was increased in the hippocampus of the pups. Exposure to PHHC also resulted in the reduced number of neurons and disrupted neuronal ultrastructure. At the same time, no changes in the content and activity of caspase-3 were found in the hippocampus of the pups. In conclusion, our findings support the hypothesis that neuroinflammation and glial activation could be involved in altering the hippocampus cellular composition following PHHC, and these alterations could be associated with cognitive disorders later in life.

show abstract

Section: Discussionmentioning

confidence: 99%

Prenatal Hyperhomocysteinemia Induces Glial Activation and Alters Neuroinflammatory Marker Expression in Infant Rat Hippocampus

Shcherbitskaia

Vasilev

Milyutina

et al. 2021

Cells

View full text Add to dashboard Cite

show abstract

“…AAV-mediated hepatic Dyrk1A gene transfer increases DYRK1A protein level in the periphery and decreases DYRK1A level in the brain of hyperhomocysteinemic mice [20]. Hyperhomocysteinemia is associated with low DYRK1A levels [41] in the periphery and with a change in inflammatory status [42,43]. Increased plasma DYRK1A levels with aging may exert an anti-inflammatory effect at the beginning of the neuropathological process, thus delaying early signs of neurodegeneration and dementia.…”

Section: Discussionmentioning

confidence: 99%

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

et al. 2023

View full text Add to dashboard Cite

Early markers are needed for more effective prevention of Alzheimer’s disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in the plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before the cognitive decline, reflecting increased risk for AD.

show abstract

“…Hyperhomocysteinemia is associated with low DYRK1A levels 39 and with a change in in ammatory status 40,41 . Increased plasma DYRK1A levels with aging may exert an anti-in ammatory effect at the beginning of the neuropathological process, thus delaying early signs of neurodegeneration and dementia.…”

Section: Discussionmentioning

confidence: 99%

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Delabar

Lagarde

Fructuoso³

et al. 2023

Preprint

View full text Add to dashboard Cite

Early markers are needed for more effective prevention of Alzheimer's disease. We previously showed that individuals with Alzheimer’s disease have decreased plasma DYRK1A levels compared to controls. We assessed DYRK1A in plasma of cognitively healthy elderly volunteers, individuals with either Alzheimer’s disease (AD), tauopathies or Down syndrome (DS), and in lymphoblastoids from individuals with DS. DYRK1A levels were inversely correlated with brain amyloid β burden in asymptomatic elderly individuals and AD patients. Low DYRK1A levels were also detected in patients with tauopathies. Individuals with DS had higher DYRK1A levels than controls, although levels were lower in individuals with DS and with dementia. These data suggest that plasma DYRK1A levels could be used for early detection of at risk individuals of AD and for early detection of AD. We hypothesize that lack of increase of DYRK1A at middle age (40–50 years) could be a warning before cognitive decline, reflecting increased risk for AD.

show abstract

Hyperhomocysteinemia alters cytokine gene expression, cytochrome c oxidase activity and oxidative stress in striatum and cerebellum of rodents

Cited by 8 publications

References 76 publications

Prenatal Hyperhomocysteinemia Induces Glial Activation and Alters Neuroinflammatory Marker Expression in Infant Rat Hippocampus

Prenatal Hyperhomocysteinemia Induces Glial Activation and Alters Neuroinflammatory Marker Expression in Infant Rat Hippocampus

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Increased plasma DYRK1A with aging may protect against neurodegenerative diseases

Contact Info

Product

Resources

About